Sema4 Holdings Corp - Ordinary Shares - Class A Stock News

On July 11, 2025, Kevin Feeley, Chief Financial Officer of GeneDx Holdings (WGS -2.00%), reported the sale of 5,278 shares of the company in multiple transactions, reducing his post-transaction holdings to 3,392 shares.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

LOS ANGELES , July 22, 2025 /PRNewswire/ -- The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws.  The investigation centers on whether the Company made false and/or misleading statements or failed to disclose material information relevant to investors.

SAN FRANCISCO , July 21, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow positive in Q4 2024 and Q1 2025 after years of net losses. Strategic restructuring, including shutting down Sema4's reproductive health unit, streamlined costs and sharpened focus on WGS's core st...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.